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Abstract 
Nonalcoholic fatty liver disease (NAFLD) frequently coexists with hyperlipidemia and conveys an 
increased cardiovascular risk, regardless of traditional risk factors. Furthermore, altered fatty acid and 
cholesterol metabolism are increasingly recognized to be central for the pathogenesis of liver injury in 
non-alcoholic steatohepatitis (NASH). Therefore, lipid-lowering drugs are attractive therapeutic tools in 
NAFLD. 
Statins ameliorated surrogate markers of steatosis in several randomized controlled trials, but their 
impact on liver histology is unknown. Furthermore, statins were the only class of lipid-lowering drugs 
to reduced cardiovascular risk in NAFLD.  
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Preliminary evidence suggests ezetimibe, an inhibitor of intestinal and hepatic cholesterol absorption,   
may improve liver histology, but its impact on CVD risk and on clinical outcomes remains to be 
determined.  
Despite strong experimental evidence supporting the use of omega-3 polyunsaturated fatty acids in 
NAFLD, the published human studies consisted of small sample size and had many methodological 
flaws, including the absence of post-treatment histology. 
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Key points 
-NAFLD is associated with an increased cardiovascular disease (CVD) risk, regardless of associated 
traditional risk factors and of fasting plasma lipid values 
-altered lipoprotein metabolism, cytokine balance and postprandial fat tolerance are believed to account 
for at least part of the increased CVD risk of NAFLD patients; there is also emerging evidence 
connecting hepatic free cholesterol accumulation to liver injury in NASH. 
-in the light of increasing evidence connecting increased hepatic free cholesterol content to liver disease 
in NAFLD, cholesterol-lowering agents are receiving much attention for the treatment of NAFLD 
-among statins, atorvastatin improved biochemical/radiological markers of steatosis in NAFLD, and 
reduced CVD events in the GREACE study. The benefit of statins on CVD risk seem to be even greater 
in patients with NAFLD than in patients with normal liver enzymes. The impact of statins on liver 
histology is unknown. 
- in the few trials available, ezetimibe improved liver histology, but its glucose-related safety needs 
further evaluation 
-these drugs may offer synergistic benefit when used in combination with each other or with other drugs 
targeting different steps of lipid/glucose metabolism. 
 4 
 
Multiple choice questions (correct answer underlined) 
1)Which are the putative mechanisms underlying the increased cardiovascular risk in NAFLD, 
independently of traditional risk factors 
a. altered lipoprotein metabolism, characterized by increased large triglyceride-rich lipoproteins, 
reduced HDL-cholesterol 
b. altered lipoprotein metabolism, characterized by increased large triglyceride-rich lipoproteins, 
reduced HDL-cholesterol, increased small LDLs 
c. altered lipoprotein metabolism, characterized by increased large triglyceride-rich lipoproteins, 
reduced HDL-cholesterol, increased small LDLs, increased oxidized LDLs 
d. altered pro/anti-inflammatory adipokine balance 
e. c+d 
 
2)Which is currently the only drug that reduced the risk of incident CVD events in randomized 
controlled trials? 
a. simvastatin 
b. rosuvastatin 
c. statins as a class overall 
d. ezetimibe 
e. polyunsaturated fatty acids 
3)what are the mechanisms whereby ezetimibe might benefit NAFLD? 
a. reduced intestinal cholesterol absorption 
b.reduced hepatic cholesterol uptake 
c. reduction in both intestinal cholesterol absorption and hepatic cholesterol uptake 
d. reduced stellate cell activation by intracellular cholesterol accumulation 
e. reduced adipokine secretion by adipose tissue 
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Introduction 
Nonalcoholic fatty liver disease (NAFLD) can be encountered in up to 30% of the general adult 
population. It is considered the hepatic manifestation of the metabolic syndrome, affecting  up to 60-
80% of diabetic and obese patients 1 . NAFLD encompasses a histological spectrum ranging from 
simple steatosis (SS) to steatosis plus necro-inflammation (non-alcoholic steatohepatitis, NASH), with 
or without fibrosis, that can only be differentiated by liver biopsy; NASH affects 3-5% of the general 
adult population and up to 20-40% of obese and diabetic subjects 1 . 
Patients with NAFLD have an increased risk not only of liver-related complications (largely confined to 
those with NASH), but also of cardiovascular disease (CVD) and of type 2 diabetes. In a recent meta-
analysis, the risk of incident and/or fatal CVD was 1.5-2-fold higher than the general population, 
respectively 2 . Importantly, the higher risk of CVD persisted even after adjusting for metabolic 
syndrome, suggesting NAFLD increases cardiovascular risk independently of associated risk factors 2 . 
Furthermore, CVD risk was increased in both SS and NASH cases, suggesting a reduction in 
cardiovascular risk should be pursued in all NAFLD patients, regardless of liver histology and of the 
presence of coexisting hyperlipidemia. 
Mechanisms underlying this association are under investigation: even in the absence of overt 
dyslipidaemia (hypercholesterolemia or atherogenic dyslipidemia, i.e. elevated triacylglycerol (TG) 
and/or low HDL-cholesterol levels), fatty liver is constantly associated with more subtle alterations in 
lipoprotein subfractions and metabolism. This is because liver TG excess drives hepatic large very low 
density lipoprotein(VLDL)-1 subfraction oversecretion, which accumulate in the blood. These compete 
with chylomicrons for lipoprotein lipase and exchange their TG with LDL and HDL particles, 
eventually leading to the highly atherogenic phenotype of small, dense LDLs, and low HDL-C 
(prevalently represented by HDL-3) 3 . Furthermore, even in the presence of normal fasting lipid 
values, NAFLD is associated with reduced tolerance to dietary fat, characterized by increased 
postprandial lipemia, enhanced pro-inflammatory response, and altered postprandial lipoprotein 
metabolism and adipokine profile following fat ingestion 4 . Lastly, dysregulated fatty acid and 
cholesterol metabolism are increasingly recognized to play a crucial pathogenic role in liver injury in 
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NASH, as discussed below. Collectively, these considerations make lipid-lowering drugs an attractive 
therapeutic measure, even in normolipidemic NAFLD patients.  
 
Cholesterol-lowering drugs 
 
Growing animal and human evidence connects altered hepatocyte cholesterol metabolism and hepatic 
free cholesterol accumulation to the pathogenesis of liver injury in NASH. Mari et al first showed 
mitochondrial free cholesterol accumulation sensitizes the liver to inflammatory stimuli in rats through 
mitochondrial glutathione depletion [5]. Subsequently, other authors have demonstrated that cholesterol 
intake is essential for determining hepatic inflammation and NASH in hyperlipidemic mouse models 
fed a Western diet, likely through direct Kupffer cell activation upon scavenging of remnant 
cholesterol-rich lipoproteins; consistently, omitting cholesterol from the high-fat diet prevented hepatic 
free cholesterol accumulation, hepatocyte injury or apoptosis, macrophage recruitment, and the 
development of diet-induced NASH 6, 7 . Recent animal and human studies elegantly elucidated the 
mechanisms underlying hepatocyte free cholesterol accumulation:  up-regulation of cholesterol 
synthesis and of low density lipoprotein receptors (LDLR) via activation of sterol regulatory element 
binding protein-2 (SREBP-2), reduced biotransformation to bile acids, and suppression of canalicular 
pathways for cholesterol and bile acid excretion in bile 7, 8 . 
In a parallel way, epidemiological studies have linked excessive dietary cholesterol intake to the 
development and severity of NAFLD, independently of caloric and macronutrient intake, even in the 
absence of overt hypercholesterolemia 9, 10 , while lipidomic analysis of human livers has shown a 
progressive increase of hepatic free cholesterol during different stages of NASH [11, 12].  
Altogether, these features make cholesterol-lowering drugs a potentially effective therapeutic approach 
in NAFLD/NASH 13, 14, 15, 16, 17, 18, 19,  20, 21   (Table 1). 
 
Statins 
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The antioxidant and anti-inflammatory properties of HMG C0-A reductase inhibitors (“statins”),, the 
frequent coexistence of NAFLD and dyslipidemia and the increased cardiovascular risk of these 
patients make statins an attractive therapeutic tool in NAFLD. Despite this premise, data on  statin 
efficacy in NAFLD are sparse, at least in part due to their feared hepatotoxicity in subjects with 
coexisting liver disease. The fear for statins hepatotoxicity has been overcome a recent Liver Expert 
Panel statement that “patients with NAFLD are not at increased risk of statin hepatotoxicity  and routine 
transaminase monitoring is not warranted in these subjects” 22 . Even their feared potential for 
worsening glucose tolerance seems largely outweighed by their well-established cardiovascular benefit 
23 .  
To date, safety and efficacy of statins in NAFLD have been evaluated in 5 randomized controlled trials  
(RCTs) (Table 1). Two small RCT with post-treatment histology evaluated  simvastatin and atorvastatin  
in NAFLD, finding either no change or an improvement in steatosis 13, 16 . While the impact of 
statins on liver histology and liver-related outcomes is largely unknown, emerging evidence suggests 
these drugs may benefit liver-unrelated clinical outcomes in NAFLD patients. For example, the Greek 
Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study was a 3-year prospective, 
randomised, open label survival study enrolling 1600 patients (78% male; 20% diabetic; 45% with 
metabolic syndrome) with established coronary heart disease (CHD), serum LDL cholesterol >2.6 
mmol/L and triglyceride <4.5 mmol/L; patients were randomized to receive statins or usual care 
(lifestyle changes, such as a low-fat diet, weight loss, and exercise, and all necessary drug treatment, 
including statin) 14  . The primary end-point was the first occurrence of any cardiovascular event.  
In a post-hoc analysis of the GREACE study,  safety and efficacy of statins were evaluated in 437 
patients (80% male; 51% diabetic; 91% with metabolic syndrome) with abnormal (< 3 x ULN) baseline 
transaminases, presumably due to  NAFLD, based on ultrasonography and exclusion of other common 
causes of abnormal liver function tests.The risk reduction in NAFLD patients was compared with the 
relative risk reduction observed between patients with normal liver tests who were treated with a statin 
and those not treated with a statin. 
Overall, statins (mainly atorvastatin 24 mg/d) were safe, with rate of discontinuation <1%  
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because of liver-related adverse effects (transaminase elevation >three-times the ULN).  Importantly,  
diabetes incidence was low (4%) in statin-treated NAFLD patients and similar to that of patients not on 
statin (4.3%).Statins improved liver function tests in NAFLD, normalizing AST, ALT and GGT in 89% 
of patients after 3 years, while liver tests worsened in NAFLD patients not receiving statins.Beside a 
reduction in LDL-C (-44% from baseline), statin-treated NAFLD patients improved also plasma  
triglyceride (-32%), HDL-C (+8%) and estimated glomerular filtration rate (EGFR) (from 59 ml/min to 
70 ml/min/1.73 m
2
, p<0.0001). Most importantly, statin treatment was associated with a significant (-
68%) risk reduction of CVD events compared with both NAFLD patients not on statin and with statin-
treated patients with normal transaminases. 
 
With all the limitation of a post-hoc analysis and  the definition of NAFLD adopted by these 
investigators,  some considerations can be drawn from this important study: 
1)statins appear safe in NAFLD and actually improve biochemical markers of liver disease (raised 
serum transaminase). The actual steatosis regression rate with statins remains however unknown, as a 
substantial number of NAFLD patients still have significant liver fat infiltration despite normal liver 
enzymes. 
1) the GREACE is the first RCT showing therapeutic benefit on clinical end-points in NAFLD. Statin-
related CVD risk reduction was greater in patients with presumed NAFLD than in those with normal 
liver tests, with a number needed to treat of 5 NAFLD patients to save 1 CVD event. Therefore, the 
risk-to-benefit ratio of long-term treatment with statins (mainly atorvastatin in this study) seems to 
favour statin administration for patients with NAFLD-related moderately abnormal liver tests. 
2) consistently with the results of a recent meta-analysis, statins are safe and do not seem to affect the 
risk of incident diabetes 23 , although their impact on insulin resistance and glucose metabolism in 
NAFLD requires further evaluation. 
3) the benefit of statins in NAFLD appear to extend to renal function. Emerging evidence connects 
NAFLD, and more consistently NASH, to an increased risk of developing chronic kidney disease,  
defined as either an estimated glomerular filtration rate of <60 mL/min/1.73 m
2
 of body surface area or 
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abnormal  proteinuria, independently of traditional risk factors, metabolic syndrome, and insulin 
resistance 24, 25, 26 . Mechanisms potentially linking obesity, NAFLD and kidney disease include 
altered fetuin-A, adiponectin and tissue 5’-AMP activated protein kinase (AMPK) expression 27  . 
Statins may benefit renal function through still unclear mechanisms, including transcriptional regulation 
of organic anion transporters (OATs) localized in the basolateral side of proximal renal tubular cells, 
like SLCO4C1, which are  involved in the renal elimination of uremic toxins and kidney 
inflammation 28, 29 .  
3) atorvastatin was the most widely used statin in the GREACE study. It is currently unknown whether 
different statins have different effectiveness in NAFLD: atorvastatin was assessed in all but 1 RCT in 
NAFLD and constantly improved biochemical and radiological surrogates of steatosis, while 
simvastatin did not change liver histology in the only RCT with post-treatment histology 13 . These 
differences may be related to the varying lipophilicity and related extrahepatic effects of different statins, 
which need to be further addressed by future research 30  (Table 2; Table 3). 
4) the median daily dose of statins  (atorvastatin 24 mg, simvastatin 22 mg, pravastatin 31 mg, and 
fluvastatin 40 mg) in NAFLD patients who normalized liver tests was similar to that used in patients 
who did not normalize liver enzymes at the end of the study. Of the measured variables, only reduction 
in plasma triglyceride correlated with ALT improvement in the GREACE population (r=0.59, p=0.002). 
Therefore, a major issue for future RCTs should be the individuation of predictors of response to statin 
in NAFLD. Patients with NAFLD are a heterogeneous population, with different mechanisms 
contributing to liver injury in the single patient. A major challenge for research will be to individuate 
those genetic or environmental factors associated with a favourable response to statin treatment, to 
tailor treatment to individual patient characteristics. 
 
Combination therapy with statins 
 
As NASH may well be a heterogeneous disease (ie a similar tissue response to more than one 
interacting pathogenic factors), several studies evaluated statins in combination with other drugs 
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targeting different factors believed to be involved in the pathogenesis of NAFLD, including oxidative 
stress and  renin-angionensin system. 
 
Foster et al conducted a post hoc analysis of the St. Francis Heart Study; they examined the effect of 
combined therapy with atorvastatin (20 mg/d), vitamin C (1 g/d), and vitamin E (1,000 IU/d) or placebo 
on 80 subjects with hepatic steatosis, assessed as the liver to spleen ratio from computed 
tomography 15 .The combination of atorvastatin with vitamins E and C significantly reduced the 
presence of NAFLD after 3.6 years (70% vs 34%; OR: 0.29; 95% CI, 0.15–0.79; P < .001). The 
improvement in hepatic steatosis was associated with significant reduction in the total and LDL 
cholesterol levels. However, 
HDL cholesterol and TG levels did not differ significantly between the two groups. The St. Francis RCT 
was originally designed to evaluate the effect of this treatment on the risk of developing CVD in healthy 
individuals deemed high risk by coronary calcium score. Several observations can be made on this 
study.  
1) The exclusion of individuals with baseline  transaminases > 1.5 x ULN  likely excluded patients with 
moderate-to-severe NASH; furthermore,  alcohol intake was not assessed, and some participants might 
actually have had alcoholic rather than non-alcoholic fatty liver.  
2) Most importantly,  it is unclear  whether the post-treatment 2.2-fold reduction in NAFLD prevalence 
in the treatment arm compared to placebo was the effect of the combination of atorvastatin plus 
antioxidants or of either agent alone, given that vitamin E showed significant benefit on liver disease in 
the 2 large “Pioglitazone versus vitamin E  for the treatment of non-alcoholic steatohepatitis” (PIVENS) 
and “Treatment of nonalcoholic fatty liver disease in children” (TONIC) trials 31, 32 .    
3)Significant reduction in NAFLD prevalence in the treatment group was still observed in patients 
with normal cholesterol and triglyceride levels at baseline and after controlling for age, sex, baseline 
BMI and blood pressure, and follow-up lipid values, suggesting that hyperlipidemia is not required 
for this treatment to be effective. Although the antioxidant effect of vitamins C and E may have 
contributed to the observed improvement, the documented antioxidant, anti-lipogenic, anti-
inflammatory and antifibrogenic  effects  of statins may also have played a relevant role (Table 2) 16,  
33, 34,  35,  36, 37, 38, 39, 40, 41, 42 . Consistent with this view,  in a small RCT enrolling 29 
normocholesterolemic overweight subjects, atorvastatin 80 mg/d reduced liver TG content by 40% 
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compared with placebo. This effect was coupled with pervasidiverse?[or persuasive? Or multiple] 
changes in hepatic expression of genes involved in lipogenesis, including a reduction in the master 
nuclear transcription factor sterol regulatory element binding protein (SREBP)-1c and in 
angiopoietin-like protein 3 (ANGPTL3), while fasting plasma glucose, NEFA and insulin sensitivity 
were unchanged 14  (Table 1). 
 
In another RCT on normocholesterolemic, nondiabetic hypertensive NAFLD patients, the combination 
of losartan plus simvastatin significantly improved steatosis as assessed by ultrasonography, abdominal 
visceral adiposity, insulin sensitivity, adiponectin  and c-reactive protein compared to amlodipine plus 
simvastatin, despite similar blood pressure reduction 17 .This study further confirms statins are 
effective in NAFLD even in the absence of overt dyslipidemia, and that may synergize with  drugs 
targeting other key pro-inflammatory pathways involved in the pathogenesis of liver disease and cardio-
metabolic risk of NAFLD. 
 
Ezetimibe  
Ezetimibe inhibits the Niemann-Pick C1 like 1 (NPC1L1) protein, which catalyzes absorption of 
cholesterol by enterocytes and hepatocytes in the gut but also the biliary canaliculi of the liver. Use of 
ezetimibe in animal models of NASH has produced promising results  43, 44  .  
In 2 nonrandomized trials, ezetimibe improved histological steatosis and necroinflammatory grade, but 
not fibrosis in NAFLD , 18,19 . These improvements were associated  with an improvement in insulin 
resistance and with a  favourable redistribution in plasma VLDL/LDL lipoprotein subfractions, in  
unsaturated/saturated fatty acid profile and in estimated desaturase activity index , 45 . 
Following these encouraging results, two RCTs assessed  ezetimibe in NAFLD. In abdominally obese 
NAFLD patients, ezetimibe plus  a low-fat diet significantly reduced magnetic resonance (MR)-
assessed liver fat content and plasma inflammatory markers compared to placebo, despite similar 
weight, waist and HOMA reduction 20    (Table 1). In the first RCT with post-treatment histology, 
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ezetimibe significantly improved histological ballooning and fibrosis, but worsened HbA1c, suggesting 
the impact of this agent on glucose metabolism needs further evaluation 21 . 
As with statins, researchers evaluated the potential synergism of combination therapy of ezetimibe with 
other agents in  NAFLD. To further reduce hepatotoxic free cholesterol accumulation, inhibition of 
cholesterol absorption by ezetimibe and synthesis by statins may offer additive benefits over either 
agent alone: this hypothesis has been currently tested in a small uncontrolled trial, where  
ezetimibe/simvastatin (10/20mg/d) significantly improved liver enzymes and atherogenic dyslipidemia 
in 19 diabetic patients with NAFLD 46 .  
The combination of ezetimibe with  alpha-glucosidase inhibitors significantly improved liver histology 
compared with either drug alone, an effect at least in part explained by synergistic effects on secretion 
of the intestinal incretin, glucagon-like peptide-1,  and on hepatic microsomal triglyceride transfer 
protein (MTP) and peroxisome proliferators-activated receptor- 1 (PPAR- 1) expression 47, 48, 49 . 
Consistent with these experimental findings, Nagai et al. reported dramatic improvement in liver 
enzymes and insulin resistance with ezetimibe+voglibose  in a single? patient with NASH, refractory to 
ezetimibe+ursodeoxycholic acid 50 .. 
 
N-3 polyunsaturated fatty acids (PUFA) 
 
 N-3 PUFA experimentally ameliorated hepatic steatosis by enhancing PPAR-α-mediated fatty acid 
catabolism and suppressing SREBP-1c-mediated de novo lipogenesis 51 . Furthermore, these agents 
possess anti-inflammatory and insulin-sensitizing properties, and also improved liver injury in animal 
models of NASH 52 . 
In a recent review, Musso et al critically appraised the published literature related to omega-3 fatty 
acids in NAFLD. They found that despite strong experimental evidence supporting their use in NAFLD, 
the published human studies consisted of small sample size and had many methodological flaws 53  
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In 5 RCTs (303 participants), PUFA improved transaminase levels, plasma triglyceride and insulin 
resistance,  and  reversed  radiological steatosis in 20-64% of cases 54, 55,  56, 57, 58  (Table 1). The 
impact of PUFA on liver histology is largely unknown: in the only RCT with post-treatment histology, 
PUFA ameliorated steatosis without affecting other histological features 58 . Overall, PUFA were well-
tolerated, with minor gastrointestinal symptoms.  
The considerable heterogeneity of study populations, treatment duration, doses, implementation of 
lifestyle intervention and of methods for assessing radiological steatosis prevents any definitive 
conclusion on these agents; further well-designed, adequately powered RCTs with histological end-
points are warranted. 
 
Probucol 
Probucol is a lipophilic lipid-lowering agent with strong antioxidant activity. It was evaluated in  NASH 
in one well-designed RCT: transaminases improved, but post-treatment histology was unavailable 59 
(Table 1). Although generally well-tolerated, probucol was associated with a significant fall  in HDL-
C, raising concerns about cardiovascular safety. 
Fibrates 
 Fibrates are PPAR-α agonists that showed consistent anti-steatogenic activity in animal models of 
NAFLD 60 . In 5 RCTs (315 participants), fibrates improved plasma lipids, but had no effect on 
radiological/histological features of NAFLD and on glucose metabolism 14,  61, 62, 63, 64  (Table 1).  
 
Conclusions 
 NAFLD is often associated with cardiovascular risk factors, including fasting and/or postprandial 
atherogenic dyslipidemia, characterized by higher triglyceride levels, increased small, dense LDL 
particles, and decreased HDL cholesterol, which may at least in part underly the increased CVD risk of 
these patients. Therefore, aggressive treatment of dyslipidemia should be considered in the overall 
framework of cardiovascular risk reduction in patients with NAFLD and associated dyslipidemia. 
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Furthermore, emerging evidence strengthens the use of lipid-lowering drugs even in NAFLD patients 
with normal fasting plasma lipids, as their CVD risk seems associated with more subtle alterations in 
lipoprotein metabolism, which are not caught by routine biochemical tests and are reversed by lipid-
lowering drugs.  In view of the global risk assessment of NAFLD patients, the NCEP ATP IV 
guidelines for the management of dyslipidemia are expected to be published in 
2012, and they will likely provide state-of-the art criteria for risk stratification and therapeutic targets 
In the meantime, patients with NAFLD should be risk stratified and managed according to their  
cardiovascular risk, and their cardiovascular risk factors should be managed based on 
their risk status 65 .  
Statins are the first line agents to treat high cholesterol: among all statins, there 
is more experience with atorvastatin, which  is the only statin to date to show a reduction in the 
incidence of CVD events in patients with NAFLD. Recent consensus panels have definitively stated the 
risk for liver injury from statins is quite rare and patients with NAFLD are not an increased risk for 
statin hepatotoxicity. Omega-3 fatty acids are perhaps the first choice to treat hypertriglyceridemia 
because of their safety, tolerability, and efficacy in improving serum triglycerides as well as their 
potential to improve the liver disease. Importantly, the effects of all lipid-lowering drugs on liver 
histology, the most widely accepted surrogate for liver-related risk, are unknown and need to be 
evaluated in future, adequately powered, well designed RCTs. 
Concerning future research, if free cholesterol overload is confirmed as a key pathogenic factor for the 
development of NASH in humans, it will be important to evaluate the most effective strategy to unload 
liver cells of free cholesterol accumulation, which could be the simultaneous inhibition of cholesterol 
synthesis and canalicular uptake by statins plus ezetimibe or simultaneous modulation of hepatic 
cholesterol synthesis, uptake and excretion by targeting key nuclear transcription factors like SREBP-2. 
 
 
 16 
Acknowledgements: this work was supported in part by grants from the Piedmont Regional Funds 
Comitato Interministeriale per la Programmazione Economica 2008. No author has any conflict of 
interest to disclose. 
 17 
 
REFERENCES 
                                                 
1Chalasani N, Younossi Z, Lavine JE, et al.The diagnosis and management of non-alcoholic fatty liver 
disease: Practice Guideline by the American Association for the Study of Liver Diseases, American 
College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 
2012;55:2005-23. 
2 Musso G, Gambino R, Cassader M, et al. Meta-analysis: natural history of non-alcoholic fatty liver 
disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 
2011;43:617-49 
3Musso G, Gambino R, De Michieli F, et al. Association of liver disease with postprandial large 
intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic 
non-alcoholic steatohepatitis. Ann Med. 2008;40:383-94 
 
4
 Musso G, Cassader M, Michieli F, et al. Adipose tissue dysfunction predicts liver histology, glucose 
and lipid metabolism in NAFLD: Role of maladaptive adipocyte response to fat ingestion. Hepatology. 
2012 Jun 8. doi: 10.1002/hep.25739. 
 
5 Marí M, Caballero F, Colell A, et al.  Mitochondrial free cholesterol loading sensitizes to TNF- and 
Fas-mediated steatohepatitis.  Cell Metab. 2006; 4:185-98. 
 
6 Wouters K,  van Bilsen M,  van Gorp PJ, et al. Intrahepatic cholesterol influences progression, 
inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Letters 2010; 
584: 1001–1005 
 18 
                                                                                                                                                                        
7 Van Rooyen DM, Larter CZ, Haigh WG,  et al. Hepatic Free Cholesterol Accumulates in Obese, 
Diabetic Mice and Causes Non-Alcoholic Steatohepatitis, Gastroenterology (2011), doi: 
10.1053/j.gastro.2011.06.040. 
8
 Min HK, Kapoor A, Fuchs M, et al. Increased hepatic synthesis and dysregulation of cholesterol 
metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012;15: 665-
74 
 
9 Yasutake K, Nakamuta M, Shima Y, et al.  Nutritional investigation of non-obese patients with non 
alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol. 2009;44: 
471-7. 
 
10 Enjoji M, Nakamuta M. Is the control of dietary cholesterol intake sufficiently effective to 
ameliorate nonalcoholic fatty liver disease? World J Gastroenterol. 2010;16: 800-3.  
11 Puri P, Wiest MM, Cheung O, et al.  A lipidomic analysis of nonalcoholic fatty liver disease. 
Hepatology 2007; 46: 1081–90. 
12 Caballero F, Fernández A, De Lacy AM,  et al. Enhanced free cholesterol, SREBP-2 and StAR 
expression in human NASH.  J  Hepatology 2009;  50:789-796 
13 Nelson A, Torres DM, Morgan AE, et al. A Pilot Study Using Simvastatin in the Treatment of 
Nonalcoholic Steatohepatitis: A Randomized Placebo-controlled Trial. J Clin Gastroenterol. 2009; 43: 
990-4. 
14  Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for 
cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek 
Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 
2010; 376:1916-22.  
 19 
                                                                                                                                                                        
15 Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic 
fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol. 2011; 
106:71-7. 
16 Pramfalk C, Parini P, Gustafsson U,  et al. Effects of high-dose statin on the human 
hepatic expression of genes involved in carbohydrate and triglyceride metabolism. J Intern Med. 2011; 
269:333-9  
 
17
 Fogari R, Maffioli P, Mugellini A, Zoppi A, Lazzari P, Derosa G. Effects of losartan and amlodipine 
alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. Eur J 
Gastroenterol Hepatol. 2012;24:164-71. 
 
18 Yoneda M, Fujita K, Nozaki Y, et al. Efficacy of ezetimibe for the treatment of non-alcoholic 
steatohepatitis: An open-label, pilot study. Hepatol Res. 2010; 40: 613-21 
19 Park H, Shima T, Yamaguchi K, et al. Efficacy of long-term ezetimibe therapy in patients with 
nonalcoholic fatty liver disease. J Gastroenterol. 2011; 46: 101-7 
20Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH Effect of ezetimibe on hepatic fat, inflammatory 
markers and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. 
Diabetes Care. 2010; 33: 1134-9 
21 Takeshita Y, Takamura T, Kita Y, et al. Efficacy of ezetimibe for the treatment of non-alcoholic 
fatty liver disease: a randomized controlled trial. J Hep 2011; 54: S346 
22Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 
2006; 97(8A): 77C-81C. 
23 Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-
analysis of randomised statin trials. Lancet. 2010; 375:735-42.  
 20 
                                                                                                                                                                        
24 Targher G, Bertolini L, Rodella S, et al. Relationship between kidney function and liver histology in 
subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol. 2010 ;5: 2166-71 
 
25 Yasui K, Sumida Y, Mori Y, et al Nonalcoholic steatohepatitis and increased risk of chronic kidney 
disease. Metabolism. 2011;60: 735-9.  
26 Arase Y, Suzuki F, Kobayashi M, et al The development of chronic kidney disease in Japanese 
patients with non-alcoholic fatty liver disease. Intern Med. 2011;50:1081-7.  
27 Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the 
roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol. 2010;21: 406-12.  
28 Suzuki T, Toyohara T, Akiyama Y, et al. Transcriptional regulation of organic anion transporting 
polypeptide SLCO4C1 as a new therapeutic modality to prevent chronic kidney disease. J Pharm Sci. 
2011; 100: 3696-707 
29 Krane V, Wanner C. Statins, inflammation and kidney disease. Nat Rev Nephrol. 2011;7: 385-97 
 
30 Wanders D,  Plaisance EP, Judd RL. Pharmacological effects of lipid-lowering drugs on circulating 
adipokines. World J Diabetes 2010; 1: 116-128 
31 Sanyal AJ , Chalasani N , Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic 
steatohepatitis . N Engl J Med 2010; 362 : 1675 – 85 
32 Lavine JE, Schwimmer JB, Van Natta ML, et al.  Effect of vitamin E or metformin for treatment of 
nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. 
JAMA. 2011 ;305:1 659-68. 
 21 
                                                                                                                                                                        
33 Vilà L, Rebollo A, Ađalsteisson GS, et al.  Reduction of liver fructokinase expression and improved 
hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Toxicol 
Appl Pharmacol. 2011; 251: 32-40. 
34 Zhang N, Huan Y, Huang H, et al, Atorvastatin improves insulin sensitivity in mice with obesity 
induced by monosodium glutamate. Acta Pharmacologica Sinica 2010; 31: 35–42 
35 Moreno M, Ramalo LN, Sancho-Bru P, et al. Atorvastatin attenuates angiotensin II-induced 
inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol 2009; 296: G147–156. 
36  Kimura Y, Hyogo H, Yamagishi S, et al. Atorvastatin decreases serum levels of advanced glycation 
endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical 
usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol. 2010; 45: 750-7. 
 
37 Maejima1 T,, Sugano1T, Yamazaki H, et al. Pitavastatin Increases ABCA1 Expression by Dual 
Mechanisms: SREBP2-Driven Transcriptional Activation and PPARα-Dependent 
Protein Stabilization but Without Activating LXR in Rat Hepatoma McARH7777 Cells. J Pharmacol 
Sci 2011;  116, 107–15 
38 Miyaki T, Nojiri S, Shinkai N, et al. Pitavastatin inhibits hepatic steatosis and fibrosis in non-
alcoholic steatohepatitis model rats. Hepatol Res. 2011;41:375-85. 
 
39 Chan DC, Nguyen MN, Watts GF, et al.  Effects of atorvastatin and n-3 fatty acid supplementation 
on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. Am J Clin Nutr. 2010; 91:900-6 
40 Calisto KL, Carvalho Bde M, Ropelle ER, et al.  Atorvastatin improves survival in septic rats: effect 
on tissue inflammatory pathway and on insulin signaling. PLoS One. 2010;5: :e14232. 
41 Quist-Paulsen P . Statins and inflammation: an update . Curr Opin Cardiol 2010 ; 25 : 399 – 405 
42 Kobayashi M, Gouda K, Chisaki I, et al. Regulation mechanism of ABCA1 expression by statins in 
hepatocytes. Eur J Pharmacol. 2011;662(1-3):9-14 
 22 
                                                                                                                                                                        
43 Zheng S, Hoos L, Cook J, et al. Ezetimibe improves high fat and cholesterol diet-induced non 
alcoholic fatty liver disease in mice. Eur J Pharmacol. 2008; 584: 118-24.  
44 Nozaki Y, Fujita K, Yoneda M, et al. Long-term combination therapy of ezetimibe and acarbose for 
non-alcoholic fatty liver disease. J Hepatol. 2009;51:548-56. 
45Park H, Hasegawa G, Shima T, et al.   The fatty acid composition of plasma cholesteryl esters and 
estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-
term ezetimibe therapy on these levels. Clin Chim Acta. 2010; 411: 21-22 
46 Abel T, Fehér J, Dinya E, et al.   Efficacy and safety of ezetimibe/simvastatin combination therapy in 
patients with type 2 diabetes and nonalcoholic fatty liver disease. Orv Hetil. 2009;150: 989-93. 
47 Nozaki Y, Fujita K, Yoneda M, et al. Long-term combination therapy of ezetimibe and acarbose for 
non-alcoholic fatty liver disease. J Hepatol. 2009;51: :548-56.  
48 Rudovich NN, Weickert MO, Machann J, Pfeiffer AF. Combination of acarbose and ezetimibe 
prevents non-alcoholic fatty liver disease: a break of intestinal insulin resistance? J Hepatol. 
2010;52:952-3. 
49 Moritoh Y, Takeuchi K, Hazama M. Combination treatment with alogliptin and voglibose increases 
active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in 
prediabetic db/db mice. Diabetes Obes Metab. 2010;12:224-33. 
 
50 Nagai K, Matsumaru K, Takahashi Y, Nakamura N. Effective therapy using voglibose for 
nonalcoholic steatohepatitis in a patient with insufficient dietary and exercise therapy: exploring other 
treatment possibilities. Case Rep Gastroenterol. 2011; 5:336-43. 
 
51
 Sekiya M,  Yahagi N,  Matsuzaka T, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in 
obese mice by SREBP-1 suppression. Hepatology 2003; 38: 1529-39. 
 23 
                                                                                                                                                                        
52
 Svegliati-Baroni G, Candelaresi C, Saccomanno S, et al. A model of insulin resistance and 
nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 
polyunsaturated fatty acid treatment on liver injury.Am J Pathol 2006; 169: 846-60 
53
 Musso G, Cassader M, Rosina F, et al. Impact of current treatments on liver disease, glucose 
metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review 
and meta-analysis of randomised trials. Diabetologia. 2012;55:885-904 
54Nobili V, Bedogni G, Alisi A, et al. Docosahexaenoic acid supplementation decreases liver fat 
content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical 
trial. Arch Dis Child. 2011;96: 350-3 
55Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects 
with nonalcoholic fatty liver disease. Dig Liv Dis 2008; 40: 194-9 
56Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from 
seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol. 
2008; 14: 6395-400 
57Cussons AJ, Watts GF, Mori TA, Stuckey BGA. Omega-3 Fatty Acid Supplementation Decreases 
Liver Fat Content in Polycystic Ovary Syndrome: A Randomized Controlled Trial Employing Proton 
Magnetic Resonance Spectroscopy. J Clin Endocrinol Metab 2009; 94: 3842–3848  
58 Caldwell SH, Argo CK, Henry TD, et al. Dissociated histological and metabolic effects of omega-3 
(3000 mg/d) vs. placebo with both exercise and diet in a double-blind randomized controlled trial of 
NASH. J Hep 2011; 54: S8 
59Merat S, Malekzadeh R, Sohrabi MR, et al. Probucol in the treatment of non-alcoholic 
steatohepatitis: a double-blind randomized controlled study. J Hepatology 2003; 38: 414-8 
60Seo YS, Kim JH, Jo NY, et al. PPAR agonists treatment is effective in a nonalcoholic fatty liver 
disease animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol. 
2008;23:102-9.  
 24 
                                                                                                                                                                        
 
61Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients 
with nonalcoholic steatohepatitis. J Hepatol 1999; 31: 384 
62Conjeevaram HS, McKenna BJ,  Kang H, et al A randomized placebo-controlled study of PPAR-
alpha agonist fenofibrate in patients with nonalcoholic steatohepatitis (NASH). Hepatology 2009; 
50(S4): 774A 
63Korenblat K, Fabbrini E, Mohammed BS, et al. Effects of fenofibrate and long-acting nicotinic acid 
on intrahepatic triglyceride content and adipose tissue insulin sensitivity in obese human subjects J Hep 
2009; 50: S25 
64 Fabbrini E, Mohammed BS, Korenblat KM, et al. Effect of fenofibrate and niacin on intrahepatic 
triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with 
nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2010 ; 95: 2727-35 
65
 Musso G, Gambino R, Cassader M. Need for a three-focused approach to nonalcoholic fatty liver 
disease. Hepatology. 2011;53:1773 
 
